Foreign cancer specialists are criticizing claims by a team of Israeli researchers who say they have developed a concept that will pave the way to a cure for cancer, with one US expert dismissing it as likely “another in a long line of spurious, irresponsible and ultimately cruel false promises for cancer patients.”

The CEO of the company behind the research told The Times of Israel on Tuesday that it has not published its research in medical journals, as is the norm, because it “can’t afford” to do so, but that the results of its pre-clinical trials have been “very good.” Several Israeli experts contacted by The Times of Israel declined to comment on the claim, some precisely because they were not familiar with the research.

“We are working on a complete cure for cancer,” said Ilan Morad, the CEO and founder of the Nes Ziona-based startup Accelerated Evolution Biotechnologies Ltd. (AEBi), in an interview with The Times of Israel on Tuesday, echoing claims the firm made to the Jerusalem Post earlier this week. “We still have a long way to go, but in the end we believe we will have a cure for all kinds of cancer patients and with very few side effects.”

Get The Start-Up Israel's Daily Start-Up by email and never miss our top stories Free Sign Up

Morad added that “in a year’s time or so” the firm could start treating patients as part of clinical trials it hopes to begin if it raises the funds. The family of molecules it has developed, which are at the core of its ostensible path to a care, have been tested in Israeli pre-clinical trials on human cancer cells in a lab and on mice, Morad said, and found effective in targeting common cancers like lung cancer, colon cancer and head and neck cancers.

Several hospitals and experts in Israel refused to comment on the claims, some noting that they had no direct information on the research. Other experts, overseas, sounded stark warnings about the researchers’ claims.

Dr. Leonard Lichtenfeld, deputy chief medical officer for the national office of the American Cancer Society, noted on Tuesday that while the Israeli scientists had worked “with an interesting approach to interfering with the ability of cancer cells to function,” their research has “apparently not been published in the scientific literature where it would be subject to review, support and/or criticism from knowledgeable peers.”

“We all have hope that a cure for cancer can be found and found quickly. It is certainly possible this approach may be work,” he wrote in a blog post entitled “A cure for cancer? Not so fast.”

“However, as experience has taught us so many times, the gap from a successful mouse experiment to effective, beneficial application of exciting laboratory concepts to helping cancer patients at the bedside is in fact a long and treacherous journey, filled with unforeseen and unanticipated obstacles.”

“It will likely take some time to prove the benefit of this new approach to the treatment of cancer. And unfortunately–based on other similar claims of breakthrough technologies for the treatment of cancer–the odds are that it won’t be successful.”

Added Lichtenfeld: “We hope that this approach also bears fruit and is successful. At the same time, we must always offer a note of caution that the process to get this treatment from mouse to man is not always a simple and uncomplicated journey.”

Dr. Ben Neel, director of Perlmutter Cancer Center at NYU Langone Health, told The New York Post that “cancer is multiple diseases, and it is highly unlikely that this company has found a ‘cure’ for cancer any more than there is a single cure for infections.”

He said that “more likely, this claim is yet another in a long line of spurious, irresponsible and ultimately cruel false promises for cancer patients.”

Publish or… research?

Morad said the team at AEBi chooses to use its scant funds to do more research rather than publishing its research in medical journals

The firm wants to focus on “advancing the research and developing more targeting peptides. It takes a lot of work and we are a small company,” he told The Times of Israel. “We can’t afford it. Publishing an article takes a lot of effort and a lot of funds, and this we can’t afford.

He added: “If we were a big company with a lot of funds, that would be the first thing we would do. If I have $100,000 what do I spend it on?” he asked. “Advancing the research and finding more and more targeting peptides, or doing many experiments to write an article? What would you do, if you had to choose?”

In the conventional process of development, medical researchers who make a discovery gather their material and submit a paper on it to legitimate medical journals in the hope that the journals’ editorial committees will validate their findings and publish the discovery. The greater the prestige of the publication, the greater the apparent value of the discovery. Researchers do not have to pay for legitimate medical journals to publish their findings.

An ‘octopus’ armed with peptides

The drug the firm hopes to develop “will be a personalized medication that will be tailored to the specific cancers of each patient,” Morad said. “Each person will get the drug for their specific cancer.”

The treatment, which the firm calls the MuTaTo (Multi-Target Toxin), is a family of molecules armed with peptides that have the ability to interact with a wide variety of proteins expressed by the cancer cells. Rather than just targeting one kind of protein, the molecules have the ability to target a number of proteins at the same time, said Morad. “We create a multiple attack on cancer,” he said.

“Think of the arms of an octopus,” he elaborated. “The octopus in this case is the molecule, and at the end of each arm there are peptides that interact with the proteins and inhibit their action.” This interaction allows “toxic peptides” attached to many arms of the octopus to penetrate the cancer cell and destroy it from within.

The results of the pre-clinical trials, Morad said, were “very good,” showing that the molecules have the ability to kill cancer cells, targeting only them and not other healthy cells. “The effect is specific to the cancer cells, leaving out other non-cancer cells, so the side effects will be much less. It will have side effects at the level of ibuprofen or a common aspirin.”

The company is now in the process of patenting the concept, he said. Funding to date has come from private investors.

Morad founded AEBi in 2000, having previously worked as a researcher at Peptor Ltd., a Rehovot-based bio-pharmaceutical firm that in 2003 got the green light for a merger with German biopharmaceutical firm DeveloGen. Other members of the team include Dan Aridor, the chairman of the board, who majored in finance at the Columbia Business School, according to the company website.

The third member mentioned on the website is Hanan Itzhaki, the chief operational officer of the firm. Itzhaki has been at the firm since 2002, having formerly worked at Rehovot-based InSight Pharmaceutical Ltd. He held a postdoctoral position at the horticultural department at Purdue University in Indiana and has a PhD from the faculty of agriculture of the Hebrew University of Jerusalem.

Morad said that the team now aims to advance its research and get to clinical trials as fast as possible.

The US Food & Drug Administration sets out procedures for the development and process of drugs as follows: “Before a drug can be tested in people, the drug company or sponsor performs laboratory and animal tests to discover how the drug works and whether it’s likely to be safe and work well in humans. Next, a series of tests in people is begun to determine whether the drug is safe when used to treat a disease and whether it provides a real health benefit.”</s>A team of Israeli scientists claim they will likely develop a cure for cancer in the next year, The Jerusalem Post reported on Monday.

The new treatment is being developed by Accelerated Evolution Biotechnologies under the leadership of CEO Dr. Ilan Morad, according to the report.

“We believe we will offer in a year’s time a complete cure for cancer,” said Dan Aridor, chairman of the company’s board. “Our cancer cure will be effective from day one, will last a duration of a few weeks and will have no or minimal side-effects at a much lower cost than most other treatments on the market.”

The treatment, called MuTaTo, will use a combination of cancer-targeting peptides and a toxin that will specifically kill cancer cells.

More at the NY Post</s>Cancer could be cured within a year, according to a researchers claim.

Cancer could be cured within a year, according to a researchers claim.

A TEAM of Israeli scientists claim they will likely develop a cure for cancer in the next year, The Jerusalem Post reported on overnight.

The new treatment is being developed by Accelerated Evolution Biotechnologies under the leadership of CEO Dr. Ilan Morad, according to the report.

"We believe we will offer in a year's time a complete cure for cancer," said Dan Aridor, chairman of the company's board.

"Our cancer cure will be effective from day one, will last a duration of a few weeks and will have no or minimal side-effects at a much lower cost than most other treatments on the market."

The treatment, called MuTaTo, will use a combination of cancer-targeting peptides and a toxin that will specifically kill cancer cells.

The treatment will eventually be personalised and a specific cocktail of the drugs will be given to patients based on their type of cancer, Dr Morad told the newspaper.

It sounds too good to be true, especially considering that an estimated 18.1 million new cancer cases are diagnosed worldwide each year, according to reports by the International Agency for Research on Cancer, with every sixth death due to cancer.

Dr Morad told thePost the company had concluded its first exploratory mice experiment, which inhibited human cancer cell growth and had no effect at all on healthy mice cells, in addition to several in-vitro trials. It was now on the cusp of beginning a round of clinical trials which could be completed within a few years and would then make the treatment available in specific case.

This article originally appeared on the New York Post and is republished here with permission.</s>A team of Israeli scientists claim they will likely develop...</s>A team of Israeli scientists claim they will likely develop a cure for cancer in the next year, The Jerusalem Post reported on Monday.

The new treatment is being developed by Accelerated Evolution Biotechnologies under the leadership of CEO Dr. Ilan Morad, according to the report.

“We believe we will offer in a year’s time a complete cure for cancer,” said Dan Aridor, chairman of the company’s board. “Our cancer cure will be effective from day one, will last a duration of a few weeks and will have no or minimal side-effects at a much lower cost than most other treatments on the market.”

The treatment, called MuTaTo, will use a combination of cancer-targeting peptides and a toxin that will specifically kill cancer cells.

The treatment will eventually be personalized and a specific cocktail of the drugs will be given to patients based on their type of cancer, Morad told the newspaper.</s>In breaking medical news, a team of Israeli scientists believe they have found a complete cure for cancer.

 David Aridor says his company, Accelerated Evolution Biotechnologies, has developed a cancer cure that will be effective from day one of diagnosis.

 More good news, Arido says the universal cure will also cost less than most other treatments on the market and works in less time.

Aridor says, the cancer cells would be killed and the patient could stop treatment within weeks. The treatment is called MuTaTo which stands for multi target toxin.

Researchers are hoping to have MuTaTo available to treat specific cases within a few years.</s>January 20, 2019. Prime Minister Scott Morrison visits Ringwood Private Hospital to announce lung cancer treatment drug, Tagrisso, is to be listed on the PBS. Previously the drug would cost $8000 per prescription, or nearly $90,000 a year. Honing his election rhetoric, Morrison says the cost to the government will be $96 million over the forward estimates, and that drugs like this are able to be put on the PBS because of good financial management by the government. (AAP VIDEO/Alex Murray)

PM announces cancer drug to be listed on the PBS will save patients $90,000 a year 1:37

A team of Israeli scientists claim they will likely develop a cure for cancer in the next year, The Jerusalem Post reported on Monday.

The new treatment is being developed by Accelerated Evolution Biotechnologies under the leadership of CEO Dr. Ilan Morad, according to the report.

“We believe we will offer in a year’s time a complete cure for cancer,” said Dan Aridor, chairman of the company’s board.

“Our cancer cure will be effective from day one, will last a duration of a few weeks and will have no or minimal side-effects at a much lower cost than most other treatments on the market.”

The treatment, called MuTaTo, will use a combination of cancer-targeting peptides and a toxin that will specifically kill cancer cells.

The treatment will eventually be personalised and a specific cocktail of the drugs will be given to patients based on their type of cancer, Dr Morad told the newspaper.

It sounds too good to be true, especially considering that an estimated 18.1 million new cancer cases are diagnosed worldwide each year, according to reports by the International Agency for Research on Cancer, with every sixth death due to cancer.

Dr Morad told thePost the company had concluded its first exploratory mice experiment, which inhibited human cancer cell growth and had no effect at all on healthy mice cells, in addition to several in-vitro trials. It was now on the cusp of beginning a round of clinical trials which could be completed within a few years and would then make the treatment available in specific case.

This article originally appeared on the New York Post and is republished here with permission.</s>(WSVN) - A small team of scientists in Israel have declared they are on the brink of releasing the first complete cure for cancer.

“We believe we will offer, in a year’s time, a complete cure for cancer,” Dan Aridor, of Accelerated Evolution Biotechnologies Ltd. (AEBi), told the Jerusalem Post.

Aridor said the team’s treatment, which they have dubbed MuTaTo, is essentially a cancer antibiotic with an approach similar to the treatment given to AIDS patients.

The treatment uses a combination of several cancer-targeting peptides for each cancer cell, reportedly eliminating the chance to be evaded by a mutation.

The treatment would also target cancer stem cells, which would prevent the cancer’s return.

“Our cancer cure will be effective from day one, will last a duration of a few weeks and will have no or minimal side-effects at a much lower cost than most other treatments on the market,” Aridor told the newspaper. “Our solution will be both generic and personal.”

The team said they have so far seen promising results on mice and hope to move to clinical trials soon.

Copyright 2018 Sunbeam Television Corp. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.</s>A group of Israeli scientists say they’ll have a cure for cancer within a year.

The treatment is being cooked up by Accelerated Evolution Biotechnologies Ltd. , a drug development company established in 2000, according to the Jerusalem Post.

“We believe we will offer in a year’s time a complete cure for cancer,” Dan Aridor, chairman of the board for AEBi, told the Post.

“Our cancer cure will be effective from day one, will last a duration of a few weeks and will have no or minimal side-effects at a much lower cost than most other treatments on the market,” Aridor added. “Our solution will be both generic and personal.”

The treatment is called MuTaTo, which stands for multi-target toxin, and is designed to act as a cancer antibiotic. MuTaTo uses several cancer-targeting peptides for each cancer cell at the same time, combined with a strong peptide toxin that would kill cancer cells, according to the Post.

“We made sure that the treatment will not be affected by mutations; cancer cells can mutate in such a way that targeted receptors are dropped by the cancer,” Dr. Ilan Morad, CEO of AEBi, said. “The probability of having multiple mutations that would modify all targeted receptors simultaneously decreases dramatically with the number of targets used.

“Instead of attacking receptors one at a time, we attack receptors three at a time — not even cancer can mutate three receptors at the same time,” Morad added.

AEBi is about to begin clinical trials that will wrap up in a few years. “Our results are consistent and repeatable,” Aridor said.</s>A small team of Israeli scientists think they might have found the first complete cure for cancer.

“We believe we will offer in a year’s time a complete cure for cancer,” said Dan Aridor, of a new treatment being developed by his company, Accelerated Evolution Biotechnologies Ltd. (AEBi), which was founded in 2000 in the ITEK incubator in the Weizmann Science Park. AEBi developed the SoAP platform, which provides functional leads to very difficult targets.

“Our cancer cure will be effective from day one, will last a duration of a few weeks and will have no or minimal side-effects at a much lower cost than most other treatments on the market,” Aridor said. “Our solution will be both generic and personal.”

It sounds fantastical, especially considering that an estimated 18.1 million new cancer cases are diagnosed worldwide each year, according to reports by the International Agency for Research on Cancer. Further, every sixth death in the world is due to cancer, making it the second leading cause of death (second only to cardiovascular disease).



 A doctor on Fox News is claiming that any doctor that gives parents an exemption from vaccinating their children should be prosecuted. Alex reveals the dark agenda to use vaccines to hurt the population.
An Israeli team of scientists claim to have developed a cure for cancer. This claim is criticized by other scientists, who say it is likely faked.